LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC

BACKGROUND: LCL161, a novel Smac mimetic, is known to have anti-tumor activity and improve chemosensitivity in various cancers. However, the function and mechanisms of the combination of LCL161 and paclitaxel in non-small cell lung cancer (NSCLC) remain unknown. METHODS: Cellular inhibitor of apopto...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chengcheng, Wang, Huangzhen, Zhang, Boxiang, Chen, Yimeng, Zhang, Yamin, Sun, Xin, Xiao, Guodong, Nan, Kejun, Ren, Hong, Qin, Sida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062899/
https://www.ncbi.nlm.nih.gov/pubmed/27737687
http://dx.doi.org/10.1186/s13046-016-0435-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062899/
https://www.ncbi.nlm.nih.gov/pubmed/27737687
http://dx.doi.org/10.1186/s13046-016-0435-7

Ejemplares similares